Tags

Type your tag names separated by a space and hit enter

[CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes].
Rev Med Suisse. 2008 Aug 27; 4(168):1812-7.RM

Abstract

Endocannabinoid system is overactivated in individuals with abdominal obesity. CBI receptors, first individualized in the brain, are also expressed in the adipocyte, the skeletal muscle, the liver, the gut, and the pancreas. Their blockade improves glucose tolerance and lipid profile, thanks increased insulin sensitivity and adiponectin levels. Rimonabant, a selective antagonist of CBI receptors, improves glucose control in patients with type 2 diabetes, treated with diet alone, metformin, sulfonylurea or insulin, while it also reduces body weight and other risk factors. Ongoing studies aim at further demonstrating the potential of rimonabant in the management of type 2 diabetes, in the prevention of type 2 diabetes and in the protection against cardiovascular complications in (diabetic) patients with abdominal obesity.

Authors+Show Affiliations

Service de diabétologie, nutrition et maladies métaboliques, CHU Sart Tilman, 4000 Liège, Belgique.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

fre

PubMed ID

18814765

Citation

Scheen, André J., et al. "[CB1 Receptor Inhibition and Glucose Metabolism: Role of Rimonabant in Type 2 Diabetes]." Revue Medicale Suisse, vol. 4, no. 168, 2008, pp. 1812-7.
Scheen AJ, Paquot N, Van Gaal LF. [CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes]. Rev Med Suisse. 2008;4(168):1812-7.
Scheen, A. J., Paquot, N., & Van Gaal, L. F. (2008). [CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes]. Revue Medicale Suisse, 4(168), 1812-7.
Scheen AJ, Paquot N, Van Gaal LF. [CB1 Receptor Inhibition and Glucose Metabolism: Role of Rimonabant in Type 2 Diabetes]. Rev Med Suisse. 2008 Aug 27;4(168):1812-7. PubMed PMID: 18814765.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes]. AU - Scheen,André J, AU - Paquot,Nicolas, AU - Van Gaal,Luc F, PY - 2008/9/26/pubmed PY - 2008/11/6/medline PY - 2008/9/26/entrez SP - 1812 EP - 7 JF - Revue medicale suisse JO - Rev Med Suisse VL - 4 IS - 168 N2 - Endocannabinoid system is overactivated in individuals with abdominal obesity. CBI receptors, first individualized in the brain, are also expressed in the adipocyte, the skeletal muscle, the liver, the gut, and the pancreas. Their blockade improves glucose tolerance and lipid profile, thanks increased insulin sensitivity and adiponectin levels. Rimonabant, a selective antagonist of CBI receptors, improves glucose control in patients with type 2 diabetes, treated with diet alone, metformin, sulfonylurea or insulin, while it also reduces body weight and other risk factors. Ongoing studies aim at further demonstrating the potential of rimonabant in the management of type 2 diabetes, in the prevention of type 2 diabetes and in the protection against cardiovascular complications in (diabetic) patients with abdominal obesity. SN - 1660-9379 UR - https://www.unboundmedicine.com/medline/citation/18814765/[CB1_receptor_inhibition_and_glucose_metabolism:_role_of_rimonabant_in_type_2_diabetes]_ L2 - http://www.diseaseinfosearch.org/result/2243 DB - PRIME DP - Unbound Medicine ER -